TREAT-NMD - Translational Research in Europe - Assessment and Treatment of Neuromuscular Diseases (FP6-LIFESCIHEALTH) (2007-01-01 - 2011-12-31) (»add to infobox)

Volker STRAUB, Christophe BEROUD, Judith VAN DEUTEKOM, Hanns LOCHMÜLLER, Veronika KARCAGI, Francesco MUNTONI, Peter STRENG, Jon TINSLEY, Serge BRAUN, Markus A. RUEGG, Fabrizia BIGNAMI, Thomas SEJERSEN, Richard HUGHES, Thomas MEIER, Carina WALLGREN-PETTERSSON, Kay DAVIES, Anna AMBROSINI, Philippe GAILLY, Miguel CHILLON RODRIGUEZ, Christophe GAILLARD, Bénédicte CHARRIN

UNIVERSITY OF NEWCASTLE UPON TYNE (UKC22 - Tyneside) (Great Britain), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR101 - Paris) (France), AKADEMISCH ZIEKENHUIS LEIDEN - LEIDEN UNIVERSITAIR MEDISCH CENTRUM (NL331 - Agglomeratie Leiden en Bollenstreek) (Netherlands), MUSKELDYSTROPHIE-NETZWERK EV (DE212 - München, Kreisfreie Stadt) (Germany), FODOR JOZSEF ORSZAGOS KOZEGESZSEGUGYI KOZPONT (HU101 - Budapest) (Hungary), IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (UKI11 - Inner London - West) (Great Britain), STICHTING EUROPEAN NEURO-MUSCULAR CENTRE (NL310 - Utrecht) (Netherlands), VASTOX PLC (UKJ14 - Oxfordshire) (Great Britain), ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES (FR104 - Essonne) (France), UNIVERSITAET BASEL (CH056 - Graubünden) (Switzerland), EUROPEAN ORGANIZATION FOR RARE DISEASES (FR101 - Paris) (France), KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden), KING'S COLLEGE LONDON (UKI11 - Inner London - West) (Great Britain), SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH04 - Zürich) (Switzerland), HELSINGIN YLIOPISTO (FI181 - Uusimaa) (Finland), MEDICAL RESEARCH COUNCIL (UKI11 - Inner London - West) (Great Britain), FONDAZIONE TELETHON (ITE43 - Roma) (Italy), UNIVERSITE CATHOLIQUE DE LOUVAIN (BE310 - Arr. Nivelles) (Belgium), UNIVERSITAT AUTONOMA DE BARCELONA (ES511 - Barcelona) (Spain), GENOSAFE SAS (FR104 - Essonne) (France), ACIES SAS (FR716 - Rhône) (France)

TREAT-NMD is a European neuromuscular network addressing the fragmentation currently hindering translational research for cutting edge therapies in rare neuromuscular diseases (NMD). It will strengthen European excellence in the treatment of rare NMD. Bringing promising cutting edge therapies into clinical settings is currently delayed by the lack of standardised protocols for preclinical animal studies, molecular diagnoses and patient assessment and management. TREAT-NMD will address this fragmentation by establishing a common road map for the progression of cutting edge therapies from laboratory to clinic, from the assessment of cellular and animal models, via issues of delivery, production and toxicology, to clinical outcome measures. This will be underpinned by the integration and establishment of pan-European patient databases and biobanks. The TREAT-NMD coordination centre (TNCC) will develop and integrate organisations and networks comprising the top researchers, clinicians and industries working in Europe (representing 11 countries) in partnership with patient organisations in order to deliver the dream of treatments for these devastating disorders. Technological, educational and communication Centres of Excellence will be generated as a durable resource co-ordinated by the TNCC, which will establish Europe as the leader in translational research in this area. A strong educational programme will provide the next generation of experts with the necessary background and expertise to maintain this leading position, and integrate the voices of patient organisations in the development of future research plans. Cutting edge treatments currently under development for muscular dystrophies and spinal muscular atrophy will be specifically targeted in this process, while future developments will also benefit from the durable infrastructure of the TNCC, which will act as the portal for future pharmaceutical developments in this field.

PERSONS (21/21)

RELATED NAVIGATION AREA(S) (1/1)